ALL	Acute lymphoblastic leukaemia
AML	Acute myeloid leukaemia
APL	Acute promyelocytic leukaemia
ATRA	All-trans retinoic acid
B-ALL	B-acute lymphoblastic leukaemia
BTK	Bruton’s tyrosine kinase
BV	Brentuximab vedotin
cHL	Classical Hodgkin lymphoma
CLL	Chronic lymphocytic leukaemia
CML	Chronic myeloid leukaemia
CR	Complete response
CTLA-4	Cytotoxic T-lymphocyte antigen 4
DLBCL	Diffuse large B cell lymphoma
DNMTi	DNA methyltransferase inhibitors
EBV	Epstein–Barr virus
EMA	European Medicines Agency
ENKL	Extranodal NK/T cell lymphoma
FDA	US Food and Drug Administration
FGF	Fibroblast growth factors
G-CSF	Granulocyte colony-stimulating factor
GM-CSF	Granulocyte-macrophage colony stimulating factor
HL	Hodgkin lymphoma
HRS	Hodgkin Reed Sternberg
ICI	Immune checkpoint inhibitor
IDO	Indoleamine-pyrrole 2,3-dioxygenase
IMC	Immature myeloid cell
IMiDs	Immunomodulatory imide drugs
IPI	International Prognostic Index
ITIM	Immunoreceptor tyrosine-based activation motif
MDSC	Myeloid-derived suppressor cells
MHC	Major histocompatibility complex
M-MDSC	Monocytic myeloid-derived suppressor cells
MYC	Myelocytomatosis proto-oncogene
NHL	Non-Hodgkin lymphoma
NK cells	Natural killer cells
NO	Nitrate reductases
ORR	Overall response rate
PBMC	Peripheral blood mononuclear cells
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
PD-L2	Programmed death-ligand 2
PFS	Progression free survival
PIWI	P-element Induced Wimpy testis
PMBL	Primary mediastinal B cell lymphoma
PMN-MDSC	Polymorphonuclear myeloid-derived suppressor cells
PR	Partial response
ROS	Reactive oxygen species
R/R	Relapse/Refractory
T-ALL	T acute lymphoblastic leukaemia
TCR	T cell receptor
TFG-β	Transforming growth factor beta
TIGIT	T cell immunoglobulin and ITIM domain
TME	Tumour microenvironment
VEGF	Vascular endothelial growth factor
VISTA	V-domain immunoglobulin suppressor of T cell activation
WNT	Wingless way